Literature DB >> 9089795

Differential effects of cyclo-oxygenase pathway metabolites on cytokine production by T lymphocytes.

S Della Bella1, M Molteni, S Compasso, C Zulian, M Vanoli, R Scorza.   

Abstract

Cyclo-oxygenase pathway metabolites released in the microenvironment by activated platelets and endothelial cells are potential local modulators of the immune response. In the present study, we have investigated the modulatory role of PGE2, iloprost (prostacyclin analogue), U-46619 (thromboxane analogue) on the release of IL-2, IFN-gamma, TNF-alpha and IL-6 by T lymphocytes. Our results show that PGE2 and prostacyclin differ in the regulation of cytokine production. PGE2 inhibited the release of IL-2 and IFN-gamma, while iloprost did not affect their production. The addition of PGE2 or iloprost greatly decreased the amount of TNF-alpha measured in the supernatants, although the rates of inhibition differed according to the kind of stimulation. Unlike that of PGE2, inhibition by iloprost was stronger in alloactivated cultures than in PHA-stimulated ones. In vitro IL-6 production was stimulated by PGE2 in alloactivated cultures and by iloprost, whatever the stimulus. These results are probably due to other cellular subsets contaminating the T-lymphocyte preparations. After complete removal of monocytes from cell cultures, there were inhibitory effects of lloprost and PGE2 on IL-6 released in the supernatants. We did not observe any significant effect of thromboxane analogue on the production of either cytokine.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9089795     DOI: 10.1016/s0952-3278(97)90531-7

Source DB:  PubMed          Journal:  Prostaglandins Leukot Essent Fatty Acids        ISSN: 0952-3278            Impact factor:   4.006


  9 in total

Review 1.  Prostaglandins and cancer.

Authors:  D Wang; R N Dubois
Journal:  Gut       Date:  2005-08-23       Impact factor: 23.059

2.  Inhaled iloprost suppresses the cardinal features of asthma via inhibition of airway dendritic cell function.

Authors:  Marco Idzko; Hamida Hammad; Menno van Nimwegen; Mirjam Kool; Nanda Vos; Henk C Hoogsteden; Bart N Lambrecht
Journal:  J Clin Invest       Date:  2007-02       Impact factor: 14.808

3.  Role of RANTES and its receptor in gastric cancer metastasis.

Authors:  Zhixin Cao; Xiangshang Xu; Xuelai Luo; Li Li; Bin Huang; Xiaolan Li; Deding Tao; Junbo Hu; Jianping Gong
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2011-06-14

4.  Decrease in circulating endothelial cell adhesion molecule and thrombomodulin levels during oral iloprost treatment in rheumatoid arthritis patients: preliminary results.

Authors:  Michael W J Boehme; Ino K Gao; Cornelia Norden; Ernst-Martin Lemmel
Journal:  Rheumatol Int       Date:  2005-02-08       Impact factor: 2.631

Review 5.  Chronic immune activation and inflammation as the cause of malignancy.

Authors:  K J O'Byrne; A G Dalgleish
Journal:  Br J Cancer       Date:  2001-08-17       Impact factor: 7.640

Review 6.  Non-Steroidal Anti-Inflammatory Drugs in the Carcinogenesis of the Gastrointestinal Tract.

Authors:  Debora Compare; Olga Nardone; Gerardo Nardone
Journal:  Pharmaceuticals (Basel)       Date:  2010-08-09

7.  XRCC5 cooperates with p300 to promote cyclooxygenase-2 expression and tumor growth in colon cancers.

Authors:  Zhifeng Zhang; Fufu Zheng; Zhenlong Yu; Jiajiao Hao; Miao Chen; Wendan Yu; Wei Guo; Yiming Chen; Wenlin Huang; Zhijun Duan; Wuguo Deng
Journal:  PLoS One       Date:  2017-10-19       Impact factor: 3.240

8.  Global tumor RNA expression in early establishment of experimental tumor growth and related angiogenesis following COX-inhibition evaluated by microarray analysis.

Authors:  Hans Axelsson; Christina Lönnroth; Marianne Andersson; Wenhua Wang; Kent Lundholm
Journal:  Cancer Inform       Date:  2007-05-01

9.  User preference for a portable syringe pump for iloprost infusion.

Authors:  Antonella Laria; Alfredo Maria Lurati; Katia Angela Re; Maria Grazia Marrazza; Daniela Mazzocchi; Alberto Farina; Magda Scarpellini
Journal:  Patient Relat Outcome Meas       Date:  2015-05-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.